Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Dianthus Therapeutics, Inc.

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
Dianthus Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics to Participate at the Guggenheim 6th Annual Biotechnology Conference
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics Announces $230 Million Private Placement
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics Enhances Leadership Team with Appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics Highlights Recent Business Achievements and Third Quarter 2023 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics to Participate in Upcoming Investor Healthcare Conferences in November
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics Announces Positive Top-line Phase 1 Data and Debuts Trading on Nasdaq as DNTH
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Magenta Therapeutics Announces Completion of Merger with Dianthus Therapeutics and Implementation of Reverse Stock Split
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.